Source: Eur Respir Rev 2011; 20: 175-182
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roche N., Marthan R., Berger P., Chambellan A., Chanez P., Aguilaniu B., Brillet P-Y, Burgel P-R, Chaouat A., Devillier P., Escamilla R., Louis R., Mal H., Muir J-F, Pérez T., Similowski T., Wallaert B., Aubier M.. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev 2011; 20: 175-182

Member's Comments

No comment yet.

Related content which might interest you: Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Emerging anti-inflammatory strategies for COPD}, Source: Eur Respir J 2012; 40: 724-741 Year: 2012 Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Source: Eur Respir J 2007; 30: 574-588 Year: 2007 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Airway epithelial inflammatory responses and clinical parameters in COPD Source: Eur Respir J 2003; 22: 94-99 Year: 2003 Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Modern treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 60S-66S Year: 2001 Implications for disease and therapy Source: Annual Congress 2005 - Oxidative and nitrative stress: control of cell function in COPD Year: 2005 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Airway pathology in asthma Source: Eur Respir J 2001; 18: 18S-23S Year: 2001 Why is it important to consider (sub)phenotypes of asthma and COPD? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design Source: Eur Respir J 2006; 27: 293-299 Year: 2006 Inflammation in COPD: a link to systemic comorbidities Source: Eur Respir Rev 2007; 16: 91-97 Year: 2007 Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Source: Eur Respir J 2007; 29: 906-913 Year: 2007 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013